Single-cell genomic approaches for developing the next generation of immunotherapies

Ido Yofe, Rony Dahan, Ido Amit

Research output: Contribution to journalArticlepeer-review

Abstract

Recent progress in single-cell genomics urges its application in drug development, particularly of cancer immunotherapies. Current immunotherapy pipelines are focused on functional outcome and simple cellular and molecular readouts. A thorough mechanistic understanding of the cells and pathways targeted by immunotherapy agents is lacking, which limits the success rate of clinical trials. A large leap forward can be made if the immunotherapy target cells and pathways are characterized at high resolution before and after treatment, in clinical cohorts and model systems. This will enable rapid development of effective immunotherapies and data-driven design of synergistic drug combinations. In this Perspective, we discuss how emerging single-cell genomic technologies can serve as an engine for target identification and drug development.

Amit and colleagues discuss where single-cell genomic technologies can be applied both in trial design and in the clinical trial stage to improve the development of immunotherapies.

Original languageEnglish
Pages (from-to)171-177
Number of pages7
JournalNature Medicine
Volume26
Issue number2
DOIs
StatePublished - 3 Feb 2020

Fingerprint

Dive into the research topics of 'Single-cell genomic approaches for developing the next generation of immunotherapies'. Together they form a unique fingerprint.

Cite this